This study's goal was to assess the safety of tumor-targeted interleukin-12 (ttIL-12) when administered by electrogenetherapy in C3H/HeJ mice by identifying an initial safe dose for human dose escalation schemes, toxicity target organs, markers of toxicity, and toxicity reversibility. Tumor-free mice receiving two doses of 0.45% NaCl, 1 mg ttIL-12 DNA in 0.45% NaCl or 5 mg ttIL-12 DNA in 0.45% NaCl, 10 days apart combined with low-intensity electroporation were compared with non-treatment controls over time. All mice had blood cell counts, serum chemistry profiles, plasma interleukin-12 and IFNg determinations, necropsy and multi-organ histopathology. Mild treatment-associated changes included electroporation-associated muscle changes that resolved by 30 days; decreased total white blood cell counts and infectious disease in the 5 mg ttIL-12 group, but not in the 1 mg group, and liver changes in ttIL-12 groups that correlated with alanine transaminase levels and resolved by 30 days. Dystrophic cardiac calcification seen in older, 5 mg ttIL-12-treated mice was the only serious toxicity. Based on these results and the lack of any effect on wound healing when combined with surgery, low-intensity electrogenetherapy with ttIL-12 appears to be safe and well tolerated. Cancer Gene Therapy (2011) 18, 265-274; doi:10.1038/cgt.2010; published online 14 January 2011
Introduction
One of the major challenges associated with traditional surgical oncology, radiation and chemotherapy is tumor recurrence and metastasis. One strategy to prevent tumor recurrence and metastasis is to induce or augment antitumor immunity. Interleukin-12 (IL-12) induces and maintains a powerful Th1-mediated anti-tumor immune response and has been used therapeutically in humans to treat neoplasia. The major effects of IL-12 are the stimulation of IFN-g production by natural killer and T cells, which in turn stimulates additional IL-12 production, 1 and induction of anti-angiogenesis genes. 2 Another important role of IL-12 is to exhibit immunoregulatory functions in the generation of T helper 1 (Th1) and cytotoxic T lymphocytes. 3 For these reasons, daily systemic administration of IL-12 recombinant protein (rIL-12) has been shown to generate a significant inhibitory effect on the metastatic tumor growth of B16F10 melanoma, established murine renal carcinoma (RENCA), and CT26 tumors 2, 4, 5 Unfortunately, rIL-12
has also been associated with significant adverse effects, including death. 6, 7 Investigation of rIL-12 toxicity suggests that cytokine-induced shock causing early deaths was mediated by natural killer cell production of IFNg. 8 Much of this toxicity was attenuated by giving low, 'desensitizing' doses of rIL-12 before treatment with the normal dose regimen; nevertheless, use of rIL-12 has now been supplanted by the use of IL-12 gene therapy for cancer treatment.
Systemic administration of cytokines at pharmacologic doses results in high concentrations of cytokines in the circulation and often in suboptimal levels in tissues at the site of tumors, therefore therapy is more likely to cause systemic toxicity and less likely to be efficacious in treating the primary tumor. In contrast, electroporation (EP)-mediated cytokine gene transfection allows localized expression of cytokine at targeted sites, avoiding deleterious side effects and resembling the normal paracrine effect of cytokines. This localized effect can be enhanced more, if the gene is somehow targeted to the specific tissue or the tumor itself.
Our laboratory has previously demonstrated and published the efficacy of intratumoral EP of the gene for IL-12. 9 Others have also found that therapy using the gene for IL-12 is safe and effective in a variety of preclinical models along with in human phase 1 trials treating melanoma. 10 However, in these safety trials B16 tumorbearing mice were used, making it difficult to extrapolate to IL-12 cancer gene therapy in general (and making it difficult to rule out variables associated with tumor burden). Moreover, the electroporation field in those studies was a much higher voltage (1300 V cm 1 ) and shorter duration (95 ms) than the parameters used in this study. 11 Our laboratory and others have found that lower voltage, longer duration pulses are associated with comparable transfection efficiency in a variety of mouse tumor models using standard reporter gene assays. [12] [13] [14] Additionally, currently available commercial electroporators deliver low voltage over longer intervals.
Safety of EP has also been examined in numerous studies and numerous EP protocols have been found to be safe and effective for most commonly used tissues. [15] [16] [17] There is some concern regarding use of EP in heart muscle, and patients with defibrillators or arrhythmias may not be good candidates for EP. 17 To our knowledge, nobody has examined the toxic effects of EP over time when applied under clinical conditions in a systematic way, nor has anyone reported the safety and toxicity of a relatively low voltage, long duration electroporation protocol; therefore we sought to characterize EP changes at numerous acute and a chronic end points using a clinical electroporator to determine if there was severe or lasting toxicity.
To increase the efficacy of anti-tumor immune induction and further address the concern of safety, we have developed a plasmid DNA vector encoding a tumortargeted peptide linked to the IL-12 gene (ttIL-12), allowing the gene product to preferentially accumulate in tumors regardless of the site of injection. In this study, the safety and toxicity of ttIL-12 was thoroughly analyzed (according to FDA (Food and Drug Administration) guidelines for investigational new drug (IND) approval) in order to determine whether this novel fusion gene can be safely used in humans under clinical circumstances.
Materials and methods
Good laboratory practice (GLP) or GLP-like protocols Serum chemistries and complete blood counts (CBCs) were performed by Antech Diagnostics (Memphis, TN), which is fully compliant with good laboratory practice regulations as set forth in 21 CFR Part 58 as well as other regulatory requirements. All other procedures, including tissue archival, quality control and data keeping procedures were conducted in GLP-like conditions (as stipulated by GLP regulations, but not certified by the FDA).
Mice
All animal use studies had approval from the Louisiana State University Institutional Animal Care and Use Committee (Baton Rouge, LA). This committee follows USPHS policy on humane care and use of laboratory animals. Young adult male and female C3H/HeJ mice were obtained from a commercial vendor (Harlan Laboratories, Indianapolis, IN), were fed ad libitum a standard diet (Harlan Teklad irradiated mouse diet 7912, Harlan Teklad, Madison, WI), and were housed in a temperature-controlled animal facility with a 12/12-h light/dark cycle. Each group for the toxicity studies consisted of six male and six female mice; the age of mice at the time of the first treatment in this study was 8.5 weeks.
Cell lines and propagation
For tumor resection and wound healing studies, SCCVII murine squamous cell carcinoma cells that are syngeneic in C3H mice, originally obtained from Dr Bert O'Malley (Baylor College of Medicine, Houston, TX) were maintained as monolayers in Dulbecco's modified Eagle medium. Tumors from study mice were harvested and confirmed to be spindyloid squamous cell carcinoma cells based on routine histopathology, cytokeratin immunohistochemistry and transmission electron microscopy. Cells were harvested from flasks using trypsin-EDTA (0.05% trypsin, 0.53 mmol l À1 EDTA; Mediatech, Manassas, VA), collected by centrifugation and washed. Cells were counted and their concentration was adjusted to 2 Â 10 5 cells per ml using sterile phosphate-buffered saline before inoculation into mice.
Tumor inoculation and monitoring
Tumor cells were inoculated in syngeneic C3H mice by intradermal injection of SCCVII cells in the caudodorsal skin. A total of 30 ml of B2 Â 10 5 SCCVII tumor cells in sterile phosphate-buffered saline was delivered to each mouse. Tumors were monitored using a digital vernier caliper and volumes were calculated using the formula 4/3p(a 2 Â b) wherein 'a' is the tumor long dimension (diameter) and 'b' is the shortest measurement perpendicular to 'a'.
Anesthesia
For all procedures requiring anesthesia, mice were anesthetized by chamber induction with 4% isoflurane in oxygen and were subsequently maintained by mask administration of isoflurane in oxygen to effect. During longer procedures, an infrared heat lamp was used for thermal support. Respiratory effort and rate along with anal tone and withdrawal reflexes were monitored throughout anesthesia.
Tumor resection surgery
When tumor areas averaged 30 000 mm 3 , mice were anesthetized, the area surrounding the tumor was clipped to remove hair and the surgical site was prepared with three alternating 70% ethanol/2% chlorhexidine scrubs. The site was draped with a sterile drape and an elliptical incision was made with minimal tumor margins (B1 mm-no effort was made to completely excise tumors beyond a minimal margin) and the tumor was removed. The skin wound was closed with two to three cruciate sutures of 5-0 silk.
Plasmid DNA encoding the tumor-targeting peptide (CHP) was inserted into the murine IL-12 gene construct immediately upstream to the p40 termination codon (Cutrera, 
Electroporation
Either skin overlying the dorsal lumbar epaxial musculature or quadriceps femoris muscle were electroporated using a fixed-voltage, four-needle array disposable electrode with a 4 mm gap delivering two 60 ms pulses of indicated voltages spaced B190 ms apart, attached to a Medpulser (Inovio, San Diego, CA) clinical electroporator. For subcutaneous (SC) application (the first treatment), either 30 ml of 0.45% saline or ttIL-12 in 0.45% saline were injected subcutaneously; within 15-20 s the electrode was inserted transcutaneously straddling the injection site, and the pulses were delivered. For intramuscular (IM) use, the same volume was injected bilaterally in the quadriceps muscles (the total volume was therefore 60 ml, and the total DNA was divided between the two limbs), followed by insertion of the electroporator needles deep into the musculature surrounding the injection site.
Toxicity study
Groups of six female mice and six male mice divided equally between no treatment controls, 0.45% NaCl EP, 1 mg ttIL-12 DNA in 0.45% NaCl and 5 mg ttIL-12 DNA in 0.45% NaCl were treated. The volumes injected were 30 ml in the case of SC treatment and 60 ml divided bilaterally into two 30 ml aliquots for IM treatment. Treatment consisted of initial SC EP followed 10 days later by IM EP. Control and treatment groups were then sacrificed at acute time points (1, 3 and 7 days) and a 30 day chronic time point. Dosages of ttIL-12 were a presumably toxic mega dose of 5 mg IL12 DNA and a therapeutic dose of 1 mg IL-12 DNA. The presumed toxic dose was chosen for determining the toxicity limit but will not be translated to humans because it would equal an impractical 22.5 mg in a 90 kg human (requiring a minimum injection of B25 ml). The therapeutic dose chosen as most likely to be translated into human trials, is 1 mg for multiple administrations, which is equal to 4.5 mg in a 90 kg human.
Surgery augmented with ttIL-12 EP study
To examine the effect of ttIL-12 electroporation gene therapy (EGT) on recovery from tumor resection surgery, groups of six male mice were treated with the aforementioned protocol, but a massive dose of 20 mg of ttIL-12 was administered during each episode of EGT.
Physical exam/behavior monitoring
A brief physical exam including body weight, respiratory rate and effort, mucus membrane character, cutaneous lesions, musculoskeletal changes and localized tissue damage was performed on each mouse the day after EP and every 7 days thereafter. Mice were also monitored for gait abnormalities and grooming behavior along with any other detectable behavioral anomalies.
CBC and chemistry analysis
Mice were anesthetized and the brachial artery was accessed through an incision created in the ventral axilla; the artery was severed and pooled blood was collected with a sterile glass pipette. Approximately 400-600 ml of blood was collected into a miniature EDTA tube (BD Microtainer Tubes, Becton, Dickenson and Company) and mixed well. The remaining blood-usually B800 ml-was collected into a miniature plasma separator tube (BD Microtainer, Becton, Dickenson and Company, Franklin Lakes, NJ) and thoroughly mixed. A blood smear was made from the EDTA blood sample and the remaining blood and plasma were sent to a private GLP lab (Antech Diagnostics) for a CBC and select chemistry analysis.
Euthanasia and gross necropsy
Under isoflurane general anesthesia, mice were exsanguinated and death was assured through cervical dislocation. All mice received a complete necropsy. Any tissue that had gross lesions (in addition to those routinely collected) was saved and processed for histopathologic examination.
Histopathology
All major perfused organs as well as any tissues with lesions (two sections of skin) were fixed in 10% neutralbuffered formalin. Routine tissues examined histologically on all mice were liver, spleen, kidneys, lungs, heart, thymus, tracheobronchial lymph nodes, brain, bone marrow (lumbar spine and femurs) and quadriceps musculature. After fixation the tissue was cut-in, embedded in paraffin, sectioned on a microtome, mounted on glass slides and stained with hematoxylin and eosin. Cover-slipped slides were examined by a pathologist and lesions were recorded. All slides and paraffin blocks were subsequently archived.
Statistical analysis
Groups in each phase of evaluation were compared with control mice using a two-tailed t-test with a confidence interval of 95%. Charts of group means include standard error bars unless indicated otherwise.
Results

Optimization of medpulser parameters
Our ultimate goal is to effectively deliver ttIL-12 gene to tumors, tissues at the margins of tumors, or systemically via musculature using EP in order to prevent tumor recurrence after primary tumor ablation. To achieve this goal, it is important to have a set of EP parameters enhancing gene delivery in multiple tissues. To determine such a set of parameters, we compared each of the clinically used applicators provided by the manufacturer (Inovio) of the electroporator used in this study. We found that using the Medpulser fixed-voltage applicator delivering 107 V cm À1 for two consecutive 60 ms pulses separated by a pause of B190 ms allowed statistically significant (P ¼ 0.002 and Po0.001) high levels of reporter gene and cytokine expression when delivered Targeted-interleukin-12 electrogenetherpy safety SD Reed and S Li both SC and IM (Figure 1a ). This applicator delivers 46 V across a 4 mm gap, four-needle electrode array that is inserted transcutaneously.
Cytokine expression after ttIL-12 EGT
In previous use of rIL-12, toxicity of IL-12 protein was seen with a large systemic acute dose of rIL-12.
It is generally agreed that low constitutive IL-12 expression kinetics are produced by IL-12 EGT and one of the advantages of EGT is local expression without significant, potentially toxic systemic levels of cytokine. To determine whether clinical application of the optimized EP parameters with ttIL-12 yielded the safe expression kinetics, we determined plasma cytokine levels in all of the sacrificed mice. The previously determined parameters yielded efficient transfection of the gene for ttIL-12 in vivo using the Medpulser as indicated by detection of significant plasma cytokine levels only in IL-12 DNAtreated mice (Figures 1b and c ), yet we found no statistically significant elevation in systemic plasma cytokine levels. Mean levels of IL-12 p70 protein peaked at about 600 pg ml À1 in the 5 mg dose group on day 3, and at B60 pg ml À1 in the 1 mg therapeutic dose group on day 7. Levels of IFNg also increased after treatment, with the mean peak value reaching B120 pg ml À1 on day 7 in the 5 mg treatment group, and B360 pg ml À1 in the 1 mg treatment group.
Thus, EP parameters using the Medpulser electroporator and four-needle electrode array were effective in numerous reporter genes and for therapeutic ttIL-12. As expected, systemic levels of IL-12 were not significant enough to potentially cause systemic toxicity. Additionally, levels of IL-12 were greater in the higher dose group-particularly on day 3. The results for IFNg were similar, but higher levels were seen in the low dose IL-12 group compared with the high dose group at acute time points. It is possible that IFNg production was higher in the lower dose ttIL-12 group because of greater attenuation of IFNg response by the high dose of ttIL-12, similar to the desensitizing dose of rIL-12 used to prevent IFNg shock and fatality in rIL-12 therapy. 7 Unfortunately, to achieve significance and make any definitive conclusions, a greater number of mice would be required.
Background lesions in C3H/HeJ mice over time As all major perfused organs were evaluated histologically, we also noted lesions that appeared to have no relation to ttIL-12 EGT therapy. Two minor changes were noted over time in all groups (without increased severity or incidence in any particular treatment group). The incidence of bronchial-associated lymphoid tissue hyperplasia increased over time and was unassociated with treatment (presumably because of environmental inhalant antigen exposure). Additionally, the incidence of incisor malocclusion and overgrowth increased as mice aged. Lymphoid hyperplasia of lymph nodes, thymus and spleen were noted in all mice (both treatment and controls) throughout the study; splenic extramedullary hematopoiesis, a common frequent finding in mice, was constant between groups and over time.
Local effects of electroporation
In order to determine the local effects of electroporation, muscle and skin were harvested from electroporation sites and examined microscopically. Focal to multifocal acute rhabdomyocyte necrosis with subsequent pyogranulomatous to granulomatous myositis followed by myoregeneration Targeted-interleukin-12 electrogenetherpy safety SD Reed and S Li and resolution were seen at site of needle electrode insertion in numerous mice in all of the groups that received IM EP (Figure 2 ). The incidence of detectable muscle damage peaked at 7 days for the ttIL-12 treated mice, and was maximal on day 1 for the 0.45% saline treated mice. These trends may reflect the more widespread tissue inflammation over time and chances of detecting a change, more than reflecting increasing severity; in fact, by day 30, no muscle lesions were detected except for a single small focus of muscle degeneration, myofiber loss and mineralization in a mouse of the 5 mg ttIL-12 treatment group (in a mouse that also had marked dystrophic cardiac calcification (DCC)). We also monitored behavior and performed periodic physical examinations of the mice after EP and found that several mice were transiently lame in one or both pelvic limbs after IM EP. Mice that were lame were rechecked periodically and clinically detectable lameness resolved completely in all mice by 7 days after IM EP. There was no relationship between the incidence or severity of lameness and the substance injected.
Liver toxicity from ttIL-12
The biggest concern regarding adverse effects from IL-12 was hepatotoxicity; therefore several lobes of liver were examined histologically for ttIL-12 EGT lesions and a scoring system was used to document severity and incidence of lesions in different treatment groups (Figure 3 ). There was a mild increase in the detection of liver lesions over time in the two ttIL-12 treatment groups, but none seen in either the control mice or the 0.45% saline treated mice (Figure 3 ). Although none of the toxicity appeared serious, the most severe lesions, and the highest incidence of lesions, were seen on day 7 ( Figure 3) . Lesion incidence and severity were also greater in the 5 mg ttIL-12 treatment group than in the 1 mg ttIL-12 treatment group, but had essentially resolved by day 30.
To determine if there were any serologic indicators of liver toxicity and to see if these analytes correlated with histologic lesions, we compared mean levels of alanine transaminase (ALT) and alkaline phosphatase activity in each group as well as levels of albumin (Figure 3 ). For alkaline phosphatase and albumin, there was no significant difference between treatment groups or over time. For ALT, there was a mild, but statistically insignificant (P ¼ 0.05), increase in treatment group deviation from controls up to day 7, which returned to normal by day 30. Levels never reached clinically relevant increases (2-3 fold higher than normal range), and levels of ALT in saline treatment groups were essentially as high as or higher than in the ttIL-12 treatment groups. Nevertheless, ALT levels did correlate with liver toxicity on an individual animal basis and is thought to be a good monitoring parameter for acute liver toxicity.
Systemic immune effects of ttIL-12 EGT
In order to determine if there were any significant systemic effects of ttIL-12 EGT on the hematopoietic system and systemic immunity, CBCs and bone marrow histology were evaluated. In the case of white blood cells, there was a trend to decreasing total counts up to day 7, which returned to normal by day 30 (Figure 4 ). The trend Targeted-interleukin-12 electrogenetherpy safety SD Reed and S Li was not significantly different from control mice in the 1 mg treatment group (P ¼ 0.053 on day 3 and P ¼ 0.109 on day 7), but was in the 5 mg treatment group (P ¼ 0.017 on day 3 and P ¼ 0.023 on day 7). The incidence of infectious disease was essentially non-existent (except possibly for mild BALT hyperplasia) in all groups except for the 5 mg ttIL-12 treatment group, which had two mice on day 30 that had severe, potentially life-threatening, infectious diseases. One mouse had a moderate to severe, multifocal to coalescing pyogranulomatous cholangiohepatitis (Figure 4b) , and the other mouse had severe, bilateral, subacute to chronic, diffuse pyogranulomatous pyelonephritis (Figure 4c ). Of note is the fact that the second mouse also was one of the mice with DCC. No effects on bone marrow or other hematopoietic parameters were noted.
DCC
In histologically evaluating all other organs for potential ttIL-12 EGT toxicity, the only other major change seen in any of the mice was seen in the day 30, 5 mg ttIL-12 treatment group, which had three mice (25%) with moderate to severe DCC ( Figure 5 ). Of these mice, one died, and one had evidence of biventricular congestive Targeted-interleukin-12 electrogenetherpy safety SD Reed and S Li heart failure (pulmonary edema with splenic and hepatic congestion) at the time it was killed. As noted above, the only fatality in the 192 mice of this study was a female in the mega dose 5 mg chronic 30-day group that died on day 22 after the IM EGT treatment. The cause of death in this mouse was thought to be biventricular congestive heart failure secondary to DCC. Aside from severe myocardial mineralization (similar to Figure 5b , but more severe), this mouse had hepatosplenomegaly due to congestion and mild hemosiderosis in the liver, spleen and lungs. In the lungs, numerous alveolar macrophages contained either erythrocytes or hemosiderin ('heart failure cells'), and the interstitial spaces surrounding major vessels were expanded. Definitive evidence of pulmonary alveolar edema was not seen, but the interval between death and post-mortem examination was estimated to be 12-24 h. The female mouse with the heart depicted ( Figure 5b ) was also in congestive heart failure at the time of sacrifice as evidenced by pulmonary edema along with hepatic and splenic congestion.
Effect of ttIL-12 EGT on wound healing
Because we anticipate combining ttIL-12 EGT with surgical resection of primary tumors, analysis of wound healing when ttIL-12 EGT was critical for assuring that the therapy did not interfere with surgical protocols. Therefore, we grossly evaluated wound healing after EGT and tumor resection in squamous cell carcinoma tumorbearing C3H mice and compared with wound healing in non-treatment controls. The last figure depicts healed tumor resection incisions 7 days after surgery in mice treated with two treatments of 20 mg ttIL-12 before surgery (Figures 6a and b) . Wound healing was subjectively evaluated by observing the time to complete wound epithelialization (n ¼ 5 mice per group). As can be seen Targeted-interleukin-12 electrogenetherpy safety SD Reed and S Li from the plot comparing wound epithelialization times (Figure 6c ), EGT treatment with massive doses of ttIL-12 produced no statistical difference (P ¼ 0.5415) in primary intention wound re-epithelialization.
Discussion
Several clinical trials are beginning or underway in humans using EP to deliver DNA in the form of vaccines or therapeutic genes; however, only one toxicology study was found in the literature using tumor-bearing mice to examine the safety of IL-12 gene EGT. 11 Furthermore, the aforementioned study used high voltage (1300 V cm À1 ), short duration (0.1 ms) EP pulses in contrast to the low voltage (107 V cm À1 ), long-duration (60 ms) pulses used in the current study. The electrode array used was also different from the one used in this study (a sixneedle array versus the current four-needle array).
Comparing the different EP parameters, we did find effective transfection using the current parameters (Figure 1 ), but it was important to also determine if these EP parameters caused any serious adverse effects. In addition to establishing the safety of the current set of EP parameters, it was also important to establish the safety of ttIL-12. Theoretically, a tumor-targeted gene should be both safer and more efficacious than a systemicallyadministered, non-targeted gene. As expected, therapeutic use of ttIL-12 EGT was found to be safe and well tolerated under conditions likely to be used for EGT clinically (Figures 2, 3 and 4) .
To our knowledge, this is also the first large scale study of IL-12 toxicity in non-tumor bearing mice, and the first examining the effects of relatively low voltage, long duration EP pulses. Tumor-bearing mice are not normal immunologically [18] [19] [20] so extrapolation from studies in tumor-bearing mice is fraught with a number of variables, which may affect toxicity and efficacy of immune therapy. Additionally, both transfection efficiencies and local EP effects vary widely depending on the EP system used.
Using these parameters, local muscle changes in response to EP were completely resolved by day 30. Interestingly, damage was more frequently detected on days 1 and 3 in the group treated with carrier onlyperhaps because of the hypotonic osmolarity of the halfstrength saline compared with DNA solutions. A protective effect of ttIL-12, other than adding colloidal pressure, seems unlikely at these acute time points but cannot be ruled out. Although the damage was detectable, albeit transient, these changes should be viewed with the perspective that inserting the 4 mm wide, four electrode array into mouse quadriceps affected a much greater muscle mass than would be commonly used in humansperhaps this would be analogous to penetrating human thighs with four equidistant railroad spikes spaced 25-50 cm apart and applying an electric field. In addition to the histologic muscle changes seen after EP, several mice were transiently lame in the pelvic limbs the day after EP, but subsequently returned to a normal gait and stance thereafter.
We chose C3H/HeJ mice in this study based on previously documented gross toxicity 21 and our previous experience suggesting that they were more sensitive to IL-12 liver toxicity than other commonly used strains of inbred mice. Concerns about the well documented 16 defective TLR4 signaling in C3H/HeJ mice were not thought to be an issue because TLR4 signaling in mice appears to serve primarily as a lipopolysaccharide response pathway. Thus, C3H/HeJ mice are immunologically normal, except for their inability to respond to lipopolysaccharide and to counter Gram negative infection. 22 Liver and immune changes were detected in this study, but are not thought to be strain specific. Liver changes have been described before with rIL-12 therapy. 21 Similar to our findings, mice in previous rIL-12 studies had foci of hepatocellular necrosis with aggregates of Kupffer cell hyperplasia. In this study we have also noted occasional neutrophil and lymphocytes interspersed within the aggregates of Kupffer cells in the acute treatment groups. Lesions in the mice in this study were mild to minimal and transient. A number of lesions correlated with minimal elevations in ALT, but we found no increase in alkaline phosphatase and no decrease in albumin as was previously seen in rIL-12 toxicity. 21 We chose not to determine levels of aspartate transaminase because this enzyme is also elevated in cases of muscle damage and is therefore not liver specific. If liver toxicity was a concern, our results suggest that monitoring serum levels of ALT during therapy would be indicated.
Immune suppression and suppressed leukocyte counts have also been described with IL-12 therapy. 21 In our Targeted-interleukin-12 electrogenetherpy safety SD Reed and S Li study, both total white cell counts and individual absolute leukocyte counts were decreased after treatment with ttIL-12. Mean absolute leukocyte counts for neutrophils, lymphocytes, monocytes and eosinophils never decreased significantly from control mice. Mean total white blood cells did decrease significantly (Po0.05) from control levels on days 3 and 7 in mice treated with 5 mg of ttIL-12. Furthermore, in the 5 mg ttIL-12 group there were two mice that developed major infectious diseases; one mouse also had concurrent severe DCC, which may have been a significant stressor predisposing the mouse to pyelonephritis (or pyelonephritis may have predisposed to DCC); the other mouse had moderate to severe cholangiohepatitis. As no other mice in the study developed serious infectious disease, there is a possibility that mega-dose ttIL-12 may cause clinically relevant immune suppression. Conversely, at therapeutically relevant doses (1 mg), ttIL-12 EGT is unlikely to cause serious immunosuppression. Nevertheless, in addition to monitoring ALT, we suggest monitoring white blood cells during therapy-especially if combined with immunosuppressive chemotherapeutics. DCC was the most serious problem potentially linked to ttIL-12 EGT. Although both of the females with clinical signs attributed to DCC (death and congestive heart failure) were well within the reported 81-89 day range for development of DCC in female C3H/HeJ mice, 23 DCC seen in the 100-day-old male mouse (which did not have signs of congestive heart failure) was well before the normal onset of 292-465 days reported previously. 23 No other mice in the study developed detectable DCC suggesting that this 16% premature incidence in the mega-dose male mice may not have been significant. Nevertheless, until additional studies are done in mice that are not predisposed to DCC, mega doses of ttIL-12 would be contraindicated in subjects with similar genetic predisposition.
DCC is common in many strains of imbred mice. 24 In C3H mice, DCC is caused by a mutation in the ABCC6 gene leading to deficiency of its protein product, MRP6.
25
MRP6 is expressed primarily in the liver and kidney but also exists in many other tissues throughout the body, and is in the family of ATP-binding cassette transporters. It has long been known that DCC can be triggered in susceptible mice by a variety of stimuli including: female sex-particularly in breeders, high fat diets, infectious agents 26, 27 hormonal status 23, 28, 29 diet, 23 and freeze-thaw injury. 20 In this study, we found that ttIL-12 EGT also appears to hasten the onset of DCC in C3H/HeJ mice.
In summary, we can conclude that ttIL-12 EGT using low-voltage, long-duration pulses is safe and welltolerated at therapeutically relevant dosages. Mild muscle changes seen after IM EP are unlikely to be a problem in humans given the small area electroporated. Transient acute decreases in total white blood cells may suggest possible mild immune suppression, so vigilant patient monitoring for infectious disease and serial CBCs would be prudent. However, no infectious diseases were seen in study mice at the clinically relevant dose of 1 mg ttIL-12. Likewise, DCC was not a problem in the 1 mg therapeutic dosage group. However, several mice (three of twelve, or 25%) were affected in the mega-dose (5 mg) group at day 30, one of which presumably died of congestive heart failure secondary to DCC. Thus, until additional information is available, people with ABCC6 gene defects or patients with pseudoxanthoma elasticum (a heritable disorder of the connective tissue, caused by defective ABCC6 gene) should be excluded from treatment with mega-dose ttIL-12 EGT. Finally, no effect of ttIL-12 EGT on wound healing was seen-even at a dosage twenty times greater than those likely to be used clinically. Thus, given the safety of this treatment modality, and superiority to wild-type IL-12 therapy (Cutrera, submitted manuscript) we strongly recommend proceeding to phase I trials.
